Core Viewpoint - The successful completion of the first atrial fibrillation pulsed electric field ablation surgery at Jinan Third People's Hospital marks a significant breakthrough in the field of arrhythmia intervention treatment, providing advanced treatment options for atrial fibrillation patients in the eastern region of Jinan [1][8]. Group 1: Procedure Details - The patient, a 71-year-old male, was diagnosed with paroxysmal atrial fibrillation and underwent the pulsed electric field ablation (PFA) technique after consultations with a renowned expert from Beijing Anzhen Hospital [3]. - The surgery was performed under general anesthesia, taking approximately 30 minutes, significantly shorter than the typical 90 minutes required for traditional radiofrequency ablation [3]. - Post-surgery, the patient experienced no discomfort, did not have any recurrence of atrial fibrillation, and showed no complications, achieving the expected outcomes [3]. Group 2: Advantages of Pulsed Electric Field Ablation - Pulsed electric field ablation offers three core advantages: 1. It utilizes non-thermal ablation through ultra-short high-voltage electric pulses, minimizing risks to surrounding tissues such as blood vessels and nerves [4]. 2. The procedure is efficient, with surgery time reduced to about one hour, allowing patients to be discharged within 1-2 days post-operation [6]. 3. It is suitable for a wide range of patients, including those with poor drug treatment responses, elderly patients, and those with complex heart structures or previous ablation failures [7]. Group 3: Institutional Impact - Jinan Third People's Hospital, as a collaborative center for the National Clinical Research Center for Cardiovascular Diseases, is committed to innovative breakthroughs in minimally invasive treatments for arrhythmias [8]. - The successful implementation of the pulsed electric field ablation surgery signifies the hospital's entry into a new phase of "precision and minimally invasive" treatment for atrial fibrillation, filling a gap in high-end arrhythmia intervention technology in eastern Jinan [8].

Summary of Pulse Biosciences (PLSE) FY Conference Call - August 13, 2025 Company Overview - **Company**: Pulse Biosciences - **CEO**: Paul Le Violette - **CFO**: John Skinner - **Industry**: Medical Technology, specifically focusing on pulsed electric field (PFA) therapies Core Points and Arguments - **Therapeutic Platform**: Pulse Biosciences is focused on a life-changing therapeutic platform utilizing nanosecond PFA technology to treat various diseases, including atrial fibrillation (AFib) and benign thyroid nodules [4][5][6] - **Market Potential**: The company targets multiple markets, including thyroid interventions, cardiac surgery, and electrophysiology (EP) ablation, with a total addressable market of approximately $6 billion, expected to double over time [19][20] - **PFA Technology**: The unique aspect of Pulse's PFA technology is its ability to deliver shorter pulse durations (in billionths of a second), which allows for non-thermal tissue ablation, reducing the risk of thermal damage and improving clinical outcomes [8][9][17] - **Clinical Applications**: The company has multiple FDA clearances and breakthrough designations for its technologies, indicating strong clinical validation and potential for market entry [10][11] Key Market Segments 1. **Thyroid Interventions**: - Targeting benign thyroid nodules, with 250,000 patients diagnosed annually in the U.S. and 150,000 leading to surgical removal [25][26] - Aims to convert surgical procedures into less invasive alternatives, preserving thyroid function and reducing recovery time [27][28] - Currently in a pilot program with plans for a limited launch across 10 centers [29][30] 2. **Cardiac Ablation**: - Focused on patients undergoing open-heart surgery who also have preoperative AFib, with only 25-30% currently receiving ablation therapy [32] - The technology aims to improve the efficiency and effectiveness of existing radiofrequency ablation methods [33] 3. **Electrophysiology (EP) Market**: - The largest market segment, with significant potential for NSPFA to enhance treatment speed and safety compared to first-generation PFA technologies [36][39] Financial Position - **Strong Balance Sheet**: The company reported over $100 million in cash at the end of the quarter, enabling execution of its strategic plans [14][40] Strategic Approach - **Hybrid Market Entry Strategy**: The company plans to pursue a combination of direct market entry and partnerships, focusing on capital-efficient approaches to maximize market penetration [20][21] Challenges and Considerations - **Clinical Data and Reimbursement**: The company acknowledges the importance of clinical data to drive adoption and is actively working on reimbursement strategies to facilitate market entry [43][47] - **Existing Codes**: There are existing codes for irreversible electroporation that could be leveraged for reimbursement, although thyroid is not currently an approved indication [47][48] Conclusion - **Future Outlook**: Pulse Biosciences is positioned for growth with its innovative PFA technology, targeting significant unmet needs in the medical market, and is optimistic about its potential to transform treatment paradigms in multiple therapeutic areas [39][41]